Abstract
The American Society of Clinical Oncology’s (ASCO) Choosing Wisely (CW) initiative recommends against the use of surveillance testing (ST) of asymptomatic women with breast cancer (BC) using advanced imaging or serum tumor biomarkers testing. We evaluated if CW impacted the use of ST in women with BC. Also, its predictors were identified.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
